Home > Press > Scientists Provide Technical Due Diligence To Investor Funds
Scientists Provide Technical Due Diligence To Investor Funds
August 30, 2005
A new venture, Bio Life Technical, including leading researchers within Nanotechnology and Personalized Healthcare, such as Professor Chris Toumazou and Professor Sir Magdi Yacoub of Imperial College, London, is being launched in London, UK, providing independent due diligence services to investors, globally. Bio Life Technical is structured to aid venture capital groups, investment banks, business angels and institutional investors by providing a single contact point and managing the technical due diligence reporting process on behalf of prospective investor clients. This will save time, resources and, therefore, money for the investment community. Professor Chris Toumazou said, “Medical Device technology is truly interdisciplinary. Bio Life Technical’s strategy of providing technical due diligence by expert professors from core disciplines and world class experts working with interdisciplinary institutes, such as Imperial College’s Institute of Biomedical Engineering, will enable a more thorough scientific evaluation of the technology.”
In addition, Bio Life Technical can estimate a quantitative commercial value for a device, even though it is at a pre-development stage without the usual financial inputs to rely on. Aiden Williamson, a partner in Bio Life Technical said “The Bio Life Technical service is a welcome development in the field of technical due diligence that will give investors a clear edge when it comes to the evaluation of investment opportunities.”
By specializing in Nanotechnology and Personalized Healthcare, Bio Life Technical is concentrating upon areas of high contemporary and future importance to the investment and financial community, industry, plus scientific and healthcare organisations. Each of the technologies could cause revolutionary and, in some cases, disruptive change in the status quo and growth prospects of most technology dependent business sectors. For this reason, Bio Life Technical retains a cross-disciplinary approach, ensuring a truly comprehensive reporting structure. The value-added element of the Bio Life Technical offering is technical analysis that cannot normally be undertaken by venture capital firms, early stage investors.
####
Contact:
Paul Constant
Bio Life Technical LLP
10 John Street
London
WC1N 2EB
United Kingdom
T: + 44 (0) 20 7067 4320
F: + 44 (0) 20 7067 4301
M: + 44 78 55 31 33 89
E: info@biolifetechnical.com
Copyright ©
Bio Life Technical LLP
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
Investments/IPO's/Splits
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013
Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory June 8th, 2013
Announcements
Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013